Literature DB >> 25843568

Molecular studies reveal a MLL-MLLT3 gene fusion displaced in a case of childhood acute lymphoblastic leukemia with complex karyotype.

Daniela Ribeiro Ney Garcia1, Thomas Liehr2, Mariana Emerenciano3, Claus Meyer4, Rolf Marschalek4, Maria do Socorro Pombo-de-Oliveira3, Raul C Ribeiro5, Marcelo Gerardin Poirot Land6, Maria Luiza Macedo Silva7.   

Abstract

Rearrangement of the mixed lineage-leukemia gene (MLL-r) is common in hematological diseases and is generally associated with poor prognosis. The mixed-lineage leukemia gene translocated to, 3 (MLLT3) gene (9p22) is a frequent MLL-r partner (∼18% of leukemias with MLL rearrangement) and is characterized by the translocation t(9;11) (p22;q23), forming an MLL-MLLT3 gene fusion. MLL-r are usually simple reciprocal translocations between two different chromosomes, although karyotypes with complex MLL-r have been observed. We present a rare case of a child with acute lymphoblastic leukemia with a complex karyotype in which the classical t(9;11) (p22;q23) was cryptically relocated into a third chromosome in a balanced three-way translocation. At the genome level, however, the MLL-MLLT3 three-way translocation still displayed both reciprocal fusion transcripts. This argues in favor for a model where a simple two-way t(9;11) (p22;q23) was likely the first step that then evolved in to a more complex karyotype. Multicolor banding techniques can be used to greatly refine complex karyotypes and its chromosomal breakpoints. Also in the presence of putative new rearrangements, Long distance inverse-PCR is an important tool to identify which gene fusion is involved.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Acute lymphoblastic leukemia; MLL gene; complex karyotype; long-distance inverse polymerase chain reaction; molecular cytogenetics

Mesh:

Substances:

Year:  2015        PMID: 25843568     DOI: 10.1016/j.cancergen.2015.02.002

Source DB:  PubMed          Journal:  Cancer Genet


  1 in total

1.  High expression of miR-363 predicts poor prognosis and guides treatment selection in acute myeloid leukemia.

Authors:  Huihui Zhang; Ninghan Zhang; Rong Wang; Tingting Shao; Yuan Feng; Yao Yao; Qingyun Wu; Shengyun Zhu; Jiang Cao; Huanxin Zhang; Zhenyu Li; Xuejiao Liu; Mingshan Niu; Kailin Xu
Journal:  J Transl Med       Date:  2019-04-01       Impact factor: 5.531

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.